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Noninvasive Monitoring of Patients With 
Hepatitis C 
Robert J. Fontana and Anna S. F. Lok 
Hepatic fibrosis is the main determinant of clinical outcomes of chronic hepatitis C. Liver 
histology is frequently considered the gold standard for assessing hepatic fibrosis. However, 
liver biopsy is associated with sampling error, interobserver variability, and potential com- 
plications. Thus, there is a need for simple, inexpensive, and reliable noninvasive means to 
assess disease severity in patients with chronic hepatitis C. Clinical examination is unreliable 
in differentiating different stages of compensated liver disease. Among the routine labora- 
tory tests, decreased platelet count, increase in the ratio of aspartate to alanine aminotrans- 
ferase (AST/ALT), and prolonged prothrombin time are the earliest indicators of cirrhosis 
and portal hypertension. Individual serum fibrosis markers have limited accuracy in pre- 
dicting hepatic fibrosis. Indices composed of a panel of markers correlate better with histo- 
logical fibrosis, but their reliability requires further validation. Currently, noninvasive 
monitoring of patients with chronic hepatitis C relies on clinical evaluation, routine labo- 
ratory tests, and ultrasound and endoscopic surveillance in patients with cirrhosis. Initial 
evaluation should focus on assessment of activity and stage of liver disease for prognostica- 
tion and decisions regarding treatment, and to rule out coinfections and other causes of liver 
disease. Subsequent follow-up should focus on detection of liver disease progression and the 
need for treatment. The frequency of monitoring and the tests used will depend on the 
patient's age, stage of liver disease, and comorbid conditions. There is an urgent need to 
develop and validate noninvasive tests that can accurately reflect the full spectrum of hepatic 
inflammation and fibrosis in chronic hepatitis C. (HEPATOLOGY 2002;36:S57-S64.) 
n important component of management of hepa- 
titis C is the clinical assessment of disease severity. A Liver histology is frequently considered the gold 
standard for establishing the severity of hepatic necroin- 
flammation and fibrosis. However, liver biopsy is associ- 
ated with risks of complications, patient discomfort, and 
expense. Therefore, tracking of liver disease progression 
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cannot rely on repeated biopsies. In addition, interob- 
server variability and sampling error may lead to errone- 
ous staging. For example, studies involving expert 
hepatopathologists showed an interobserver agreement in 
fibrosis staging ranging from 70% to 90% and an intraob- 
server agreement of 60% to 90%.1,2 The level of agree- 
ment for necroinflammation was uniformly lower. 
Studies comparing needle biopsy specimens with laparo- 
scopic examination of the liver reported an underestima- 
tion of cirrhosis in 15% to 30% of patients, while studies 
of multiple liver biopsies obtained from the right lobe of 
the liver showed a sampling error of 10% to 20%.3,* 
These findings are not surprising because a 2 cm core of 
liver tissue represents only 1/50,00Oth of the entire organ. 
A noninvasive means of assessment of disease activity 
and stage would be very helpful, particularly in monitor- 
ing patients with chronic hepatitis C virus (HCV) infec- 
tion over time. An ideal test would be simple, readily 
available, inexpensive, accurate, and sensitive to the ef- 
fects of therapy (Table 1). At present, the available non- 
invasive means of assessing liver disease severity and stage 
are imperfect and lack accuracy and reliability. Noninva- 
sive approaches to assessment of severity of hepatitis C 
s57 
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Table 1. Criteria for Ideal Noninvasive Tests for Monitoring 




Accurate prediction of the full spectrum of liver disease 
Reproducible 
Sensitive to the effects of treatment 
Useful in tracking disease progression 
include clinical symptoms and signs, routine biochemical 
and hematologic blood tests, serum markers of fibrosis 
and inflammation, combinations of clinical and blood 
test results, quantitative assays of hepatic function, and 
radiologic imaging studies (Table 2). 
Clinical Features of Disease Severity 
Clinical symptoms and signs of liver disease are often 
unreliable in assessing disease severity in patients with 
compensated liver disease. A variety of symptoms includ- 
ing fatigue, itching, and right upper abdominal discom- 
fort, as well as impaired quality of life, occur in patients 
with chronic hepatitis C, but symptoms and quality of life 
scores correlate poorly with liver disease severity. Like- 
wise, physical findings of chronic liver disease, such as 
jaundice, pedal edema, hepatosplenomegaly, ascites, and 
encephalopathy, are frequently absent until patients de- 
velop decompensated cirrhosis. 
Adverse outcomes of chronic hepatitis C including 
liver failure, hepatocellular carcinoma, and death rarely 
occur in pre-cirrhotic patients. Despite improvements in 
the efficacy of treatment of chronic hepatitis C, therapy is 
not recommended for all patients because of the indolent 
course in some patients, and the expense, unpleasant side 
effects, and low overall efficacy (50% to 60%) of current 
treatment. Thus, accurate determination of the extent of 
hepatic fibrosis or stage of liver disease is important for 
prognostication, decisions regarding treatment, and mon- 
itoring of disease progression. 
Although clinical and historical data have been shown 
to correlate with rate of fibrosis progression, their accu- 
racy in predicting stage of fibrosis on liver biopsies is low. 
In a study of 2,235 French patients with chronic hepatitis 
C, Poynard et al5 identified 3 independent factors associ- 
ated with an increased rate of hepatic fibrosis: age at in- 
fection older than 40 years, daily alcohol consumption of 
50 g or more, and male sex. However, the same investiga- 
tors found that the discriminatory value of these 3 clinical 
factors for significant (Metavir score F2 to F4) as well as 
advanced fibrosis (Metavir score F3 and F4) was inferior 
compared with a 5-marker biochemical index (vide infra) 
(T. Poynard, personal communications, April 2002). A 
poor correlation between estimated fibrosis based on the 3 
historical factors listed previously and histological fibrosis 
was also observed in a study of 106 Canadian patients.6 
Thus, clinical and historical data alone cannot reliably 
predict hepatic fibrosis in patients with chronic hepatitis 
C. Other clinical factors that have been shown to be as- 
sociated with more severe or rapidly progressive liver dis- 
ease include coinfection with hepatitis B virus or human 
immunodeficiency virus, and long-term immunosuppres- 
sive therapy.71~ 
Routine laboratory Tests 
Laboratory tests that are routinely included in the eval- 
uation of patients with hepatitis C include a serum panel 
of liver tests (albumin, total bilirubin, aspartate amino- 
transferase [AST], alanine aminotransferase [ALT] , and 
alkaline phosphatase), prothrombin time, and complete 
blood counts. Serum ALT levels reflect liver injury, but 
the correlation between ALT levels and necroinflamma- 
tory and fibrosis scores is p0or.7.~ Despite the poor quan- 
titative correlation, most patients with persistently 
normal ALT levels (at least 3 normal values over a 6 to 12 
month period) have less inflammation and fibrosisg-' and 
slower rate of fibrosis progression compared with patients 
with elevated ALT levels. One study found that AST had 
a stronger correlation with liver histology, in particular 
hepatic fibrosis." Reversal of AST/ALT ratio was ob- 
served when patients progress from chronic hepatitis to 
cirrhosis12 and AST/ALT ratio of more than 1 had been 
reported to have very high specificity (82% to 100%) for 
cirrhosis.'3-16 Serum albumin, bilirubin, and prothrom- 
bin time reflect hepatic function, but these values fre- 
quently remain normal in patients with compensated or 
early cirrhosis. 
Among the routine laboratory tests, decreased platelet 
count, reversal of AST/ALT ratio, and prolonged pro- 
thrombin time are the earliest indicators of cirrhosis. 15-22 
A study of 323 patients with chronic hepatitis C found 
that platelet count or prothrombin time tested at a single 
time point was predictive of significant hepatic fibrosis 
(Metavir score F2 to F4 [T. Poynard et al., personal com- 
Table 2. Noninvasive Methods to Monitor Patients With 
Chronic Hepatitis C 
History and physical examination 
Routine laboratory tests-liver panel, complete blood count with platelets, 
Serum markers of fibrosis and inflammation 




*For patients with cirrhosis or significant fibrosis. 
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Table 3. Serum Markers of liver Fibrosis 
Markers Clearance Ohsewations 
~ ~~ 
Products of collagen synthesis/degradation 
PlllNP Hepatic and renal Marker of early fibrogenesis and inflammation, correlate better 
with histologic inflammation than fibrosis, levels decline with 
interferon therapy 
Type IV collagen 
TIMP-1 lntravascular Circulating inhibitors of MMP enzymes that can enhance 
MMP lntravascular MMP's degrade extracellular matrix, weak correlation with 
Hepatic and renal Marker of fibrolysis; levels decline with IFN therapy 
Extracellular matrix enzymes 
fibrogenesis (TIMP-1); rapidly cleared from serum 
fibrosis stage 
Extracellular matrix components 
Hyaluronic acid 
Laminin 
Hepatic endothelium and renal 
Hepatic endothelium 
Glycosaminoglycan produced by stellate cells, levels increased 
in patients with cirrhosis, levels decline with IFN therapy 
Basement membrane glycoprotein; levels may reflect severity of 
portal hypertension 
Others 
Transforming growth factor-beta Hepatic/intravascular Marker of fibrogenesis, Single most important cytokine involved 
in stellate cell activation and proliferation, presence in 
platelets makes accurate measurement difficult, levels 
decline with interferon therapy 
in patients with moderate fibrosis, sensitive to fibrosis 
progression over time 
YKL-40 ? Hepatic 38 kd glycoprotein produced by stellate cells; levels increased 
munication, April 20021). Preliminary analysis of the 
baseline data of 667 hepatitis C patients enrolled in the 
HALT-C (Hepatitis C Antiviral Long-term Treatment 
against Cirrhosis) trial found that a multivariate logistic 
regression model comprising platelet count, AST/ALT 
ratio, alkaline phosphatase, and prothrombin time was 
predictive of cirrhosis.23 In other studies of patients with 
chronic liver disease undergoing surveillance endoscopy, a 
low platelet count and prolonged prothrombin time cor- 
related with the presence and size of esophageal varices, 
but the specificity for the presence of varices was low 
(58%).24 Other investigators have also proposed that a 
composite index that includes platelet count and serum 
bilirubin levels may be a useful means of identihing pa- 
tients with HCV-related cirrhosis who should undergo 
surveillance for hepatocellular carcinoma.25 These studies 
suggest that combinations of routine laboratory tests may 
be used to predict significant fibrosis or cirrhosis in 
chronic hepatitis C patients, but the sensitivity and spec- 
ificity of these tests is suboptimal (70% to 80% at best). In 
addition, the validity of these tests/models in the general 
population of hepatitis C patients remains to be deter- 
mined. 
Serum Markers of Fibrosis and 
Inflammation 
In attempts to improve the accuracy of predicting his- 
tological activity and fibrosis, many investigators have ex- 
plored the use of serum markers of inflammation and 
fibrosis. Ideally, serum markers of inflammation and fi- 
brosis should be simple, inexpensive, readily available, 
reproducible, and accurate. Potential markers of fibrosis 
include products of collagen synthesis or degradation, en- 
zymes involved in matrix biosynthesis or degradation; 
extracellular matrix glycopro teins, and proteoglycans/gly- 
cosaminoglycans (Table 3 ) .  For these markers to accu- 
rately reflect hepatic fibrogenesis or fibrolysis, they should 
be organ-specific and the biological half-life should be 
independent of urinary and biliary excretion as well as 
sinusoidal endothelial uptake. Unfortunately, none of the 
available markers fulfill all these criteria. 
Serum hyaluronic acid and N-terminal propeptide of 
type I11 collagen (PIIINP) levels have been most exten- 
sively evaluated in patients with chronic hepatitis C. In- 
crease in serum hyaluronic acid level may be a result of 
increased hepatic stellate cell production as well as a de- 
crease in removal by hepatic sinusoidal endothelial cells. 
Several studies showed that serum hyaluronic acid levels 
correlate with the degree of hepatic fibrosis in patients 
with chronic hepatitis C.26,27 The primary role of testing 
for serum hyaluronic acid level is to identify patients with- 
out cirrhosis (greater than 90% negative predictive value). 
One study of 486 chronic hepatitis C patients found that 
a serum hyaluronic acid level of less than 60 pg/L had 
99% accuracy in predicting absence of cirrhosis on liver 
histology (negative predictive value), but the accuracy of 
serum hyaluronic acid level in diagnosing cirrhosis was 
low (30% positive predictive value).26 Serum levels of 
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PIIINP correlate better with inflammation and are infe- 
rior to serum hyaluronic acid levels in predicting hepatic 
fibrosis.27 Recently, serum YKL-40 has been reported to 
be superior to hyaluronic acid levels in predicting hepatic 
fibr0sis.2*,~9 YKL-40 is a mammalian member of a chiti- 
nase family with a molecular weight of 40 kd. The phys- 
iologic functions of YKL-40 are unknown. The protein is 
expressed in human liver and may be involved in the 
remodeling of the extracellular matrix. A recent study of 
129 patients with different causes of chronic liver disease 
found that serum YKL-40 levels were increased, even in 
patients with mild fibrosis, and correlated better with his- 
tological fibrosis scores than serum hyaluronic acid lev- 
els.28,29 Further studies in larger numbers of patients are 
needed to confirm the utility of testing for YKL-40 levels 
in assessing hepatic fibrosis in patients with chronic hep- 
atitis C. 
Based on available data, it is unlikely that individual 
serum markers of fibrosis can replace liver histology. 
Whether a combination of markers will have better accu- 
racy remains to be determined. In an ongoing study in 
Europe, a panel of 10 markers were evaluated; PIIINP, 
hyaluronic acid, tissue inhibitory metalloprotease-1 
(TIMP- I), and collagen 1V correlated best with histolog- 
ical fibrosis sc0rcs.3~ The final results of this study are 
awaited. 
Other investigators have studied a combination of rou- 
tine laboratory tests and serum markers of fibrosis and 
inflammation. One study of 339 patients with chronic 
hepatitis C found that an index based on patient age and 
gender combined with 5 biochemical markers (total bili- 
rubin, haptoglobin, gamma glutamyl transpeptidase, al- 
pha-2 macroglobulin, and apolipoprotein Al )  was the 
most accurate in identifying patients with significant he- 
patic fibrosis.3' An index of 0 to 0.10 had a 100% negative 
predictive value, while an index of 0.60 to 1.00 had a 
greater than 90% positive predictive value for a Metavir 
score of F2 to F4. Inclusion of other markers did not 
improve the predictive value. Subsequenc studies from the 
same investigators found that the 5-marker index was su- 
perior to historical data (age at infection and alcohol con- 
sumption), platelet count, or prothrombin time in 
predicting significant fibrosis (Metavir score of F2 to F4) 
or advanced fibrosis (F3 and F4). These findings are very 
encouraging but need to be validated in other laboratories 
and other patient populations. A major limiting factor in 
the use of this index is that 50% of the patients fall into 
the intermediate zone (index 0.20 to 0.80) where the 
predictive accuracy is low. In addition, the index was de- 
signed to detect the presence of clinically significant fibro- 
sis. It has a low negative predictive value for mild fibrosis. 
Thus, the ability to differentiate among varying degrees of 
hepatic fibrosis is limited. Furthermore, all except one 
study on the 5-marker index were cross-sectional and the 
utility of the index in monitoring disease progression re- 
mains to be determined. 
Quantitative Tests of Liver Function 
Quantitative tests of liver function are based on the 
turnover of a test substance, which is metabolized almost 
exclusively by the liver. Clearance of the substrate is de- 
termined by hepatic blood flow (hepatic artery and portal 
vein) and hepatic metabolic capacity. A variety of oral and 
intravenously administered metabolic probes, such as 
aminopyrine, galactose, and monoethyl glycine xylidide, 
have been evaluated. In general, these metabolic tests can 
reliably differentiate patients with compensated versus de- 
compensated cirrhosis. Tests of hepatic metabolism and 
tests of hepatic blood flow (indocyanine green clearance) 
have been used mainly in the prediction of survival of 
patients with cirrhosis, especially after s~rgery,3~ but their 
ability to identify patients with mild or moderate fibrosis 
has not been properly examined. 
A recent study compared 2 tests of hepatic metabolism 
(aminopyrine breath test and galactose elimination capac- 
ity) and 2 tests of hepatic blood flow (indocyanine green 
clearance and sorbitol clearance) in 367 patients with 
chronic hepatitis B or C, and 25 age-matched healthy 
controls.33 The investigators found that metabolic liver 
function was significantly decreased even in patients with 
mild or moderate fibrosis. In contrast, hepatic perfusion 
declined only in patients with severe fibrosis or cirrhosis. 
These data suggest that tests of hepatic metabolic function 
may be used in assessing hepatic fibrosis. However, these 
tests are cumbersome and expensive and unlikely to be 
applicable in clinical practice. In addition, the perfor- 
mance (predictive values for different stages of fibrosis) of 
these tests was not analyzed and their accuracy in compar- 
ison with simpler more readily available tests was not dis- 
cussed. 
Radiologic Imaging 
Ultrasound and other imaging techniques such as 
computed tomography and magnetic resonance imaging 
can be used to diagnose cirrhosis based on the presence of 
an enlarged spleen, small nodular liver, ascites, and intra- 
abdominal varices. In addition, radiologic imaging can 
detect hepatocellular carcinoma. However, ultrasound is 
highly operator-dependent while computed tomography 
and magnetic resonance imaging are very expensive. In 
addition, the presence of increased liver echogenicity on 
ultrasound does not reliably differentiate hepatic steatosis 
from fibrosis. Furthermore, current imaging techniques 
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are unable to assess the extent of hepatic fibrosis and are 
not sufficiently sensitive to detect early cirrhosis. A recent 
study examined 12 clinical and 11 Doppler ultrasonic 
variables in 243 patients with chronic (alcoholic and viral) 
liver disease among whom 45% had evidence of clinical 
decompensation (ascites or encephalopathy). The diag- 
nostic accuracy of Doppler ultrasound for cirrhosis 
among the 83 patients with chronic hepatitis was 86% 
(positive predictive value, 62%; negative predictive value, 
92%).3* Nodularity on the liver surface was the most 
discriminatory ultrasound feature. These data suggest 
that cirrhosis can be diagnosed by ultrasound in 60% to 
80% of patients in the best of hands. However, the gen- 
eralizability of these data to clinical practice is uncertain. 
In addition, the investigators acknowledged that not all 
patients in the study could be evaluated because of ana- 
tomic limitations. Recently, contrast-enhanced Doppler 
ultrasonography has also been reported to increase the 
accuracy of the diagnosis of cirrhosis.35 These data are 
preliminary and require confirmation by other groups. 
Radionuclide liver spleen scans using technetium 
99m-labeled sulphur colloid taken up by Kupffer cells 
have also been used to assess hepatic functi0n.3~ This 
technique is sensitive in diagnosing cirrhosis, but there is 
very little data on its accuracy in detecting mild or mod- 
erate hepatic fibrosis. The expense of this test and its low 
sensitivity in detecting early fibrosis limit its clinical use in 
patients with chronic hepatitis C. 
Recommendations on Noninvasive 
Monitoring 
Significant progress has been made in the noninvasive 
assessment of hepatic fibrosis. However, none of the tests 
or indices discussed previously will, on their own, replace 
liver histology as a means of assessing activity and stage of 
disease in the near future. Additional refinement and val- 
idation of these tests and indices are necessary to confirm 
their applicability in clinical practice and their value, not 
only in the initial assessment of patients, but also in mon- 
itoring disease progress. Ideally, these tests and indices 
should provide accurate prediction of the full spectrum of 
liver disease, not just dichotomous outcomes. Noninva- 
sive tests that could reliably distinguish moderate to severe 
fibrosis from mild fibrosis may also prove useful to clini- 
cians for treatment decisions and disease monitoring. 
Recommendations on noninvasive monitoring of pa- 
tients with chronic hepatitis C in 2002 will continue to 
rely on clinical evaluation, routine laboratory tests, and 
standard imaging. The reader should be aware that the 
following recommendations have not been validated in 
prospective studies. Because the appropriate monitoring 
plan will vary in light of the relevant facts and circum- 
Table 4. Initial Noninvasive Evaluation of Patients With 
Chronic HeDatitis C* 
Histoly 
Symptoms 





HCV tests-HCV RNA, HCV genotype 
Tests to rule out HBV and HIV coinfection and other cause of liver disease 
Tests to assess liver disease severity-liver panel, blood counts with platelets, 
Test to detect hepatocellular carcinoma-alpha-fetoprotein 
prothrombin time 
Abdominal ultrasound 
*Baseline liver biopsy is useful in patients above the age of 40, patients who 
wish to defer treatment, and patients with relative contraindications to treatment. 
stances surrounding each individual patient with chronic 
hepatitis C, these recommendations are intended to serve 
as guidelines and not “standards of care,” and may be 
updated as new information becomes available. 
I ni tia I Eva lu a ti on 
The initial evaluation of patients with chronic hepatitis 
C should focus on assessment of activity and stage of liver 
disease for prognostication, decisions regarding treat- 
ment, and to rule out other causes of liver disease (Table 
4).  Patients should undergo a thorough history and phys- 
ical examination to estimate the age at infection, quantify 
alcohol consumption, and to evaluate symptoms and 
signs of chronic liver disease. 
A sensitive test for HCV RNA is recommended in 
patients with antibody to HCV (anti-HCV) who have 
normal ALT levels and no risk factors for infection, be- 
cause up to 30% of these individuals may have resolved 
infection or a false-positive anti-HCV test result. In con- 
trast, the pretest probability is high in anti-HCV-positive 
patients with risk factors andlor clinical or biochemical 
evidence of chronic liver disease. Therefore, a confirma- 
tory test for HCV RNA is not mandatory but is highly 
recommended because patients with risk factors may have 
resolved HCV infection and other causes of aminotrans- 
ferase elevations (e.g., fatty liver disease, alcohol). Quan- 
titative HCV RNA levels and HCV genotypes do not 
correlate with disease severity, but these tests should be 
performed in patients who are considered for therapy be- 
cause the results are useful in predicting the likelihood of 
an antiviral treatment response and in planning the dura- 
tion of therapy. 
The initial laboratory tests should include a liver panel, 
complete blood counts with platelet counts, prothrombin 
time, and alpha-fetoprotein. As discussed previously, de- 
creased platelet count, reversal of AST/ALT ratio, and 
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Table 5. LongTerm Noninvasive Monitoring of Patients With 
Chronic Hepatitis C 
Abnormal ALT 
Mild Significant 
Persistently liver Rbrosis or 
Normal ALT Disease Cirrhosis 
Frequency 6 to 12 rnos 6 rnos 6 mos 
History and physical + + + 
Routine lab tests + + i 
Alpha-fetoprotein - - 
Ultrasound 





*Every 2 years. 
prolongation of prothrombin time indicate that the pa- 
tient may have advanced fibrosis or cirrhosis. Laboratory 
tests at presentation should also include tests for other 
causes of liver disease such as hemochromatosis (iron sat- 
uration) and hepatitis B (hepatitis B surface antigen) and 
tests for antibody to human immunodeficiency virus in 
patients with risk factors. A baseline abdominal ultra- 
sound should be considered, particularly for patients 
above the age of 40, to determine if there are features 
suggestive of cirrhosis and to rule out focal lesions in the 
liver. Assessment of underlying autoimmune disorders, 
thyroid dysfunction, neuropsychiatric illnesses, and cor- 
onary artery disease should be carried out before initiation 
of treatment. 
Despite the shortcomings of liver biopsies, a baseline 
liver biopsy may be very useful, especially in patients 
above the age of 40 and patients who wish to defer treat- 
ment. 
Monitoring of treatment response and adverse effects 
will be discussed in detail in the sections on treatment. 
LongTerm FolloWUp 
The frequency at which hepatitis C patients should be 
monitored and the tests that should be performed depend 
on the age of the patients, stage of liver disease, and co- 
morbid conditions (Table 5) .  Decisions regarding treat- 
ment as well as re-treatment should be re-evaluated in 
patients who have had progression of liver disease, reso- 
lution of contraindications to treatment, improvement, 
or stabilization of comorbid illnesses. Re-evaluation is also 
needed as each better-tolerated and more effective treat- 
ments become available. 
Patients with detectable serum HCV RNA, persis- 
tently normal ALT levels and no clinical, laboratory, and 
radiologic evidence suggestive of cirrhosis may be moni- 
tored at less frequent intervals. Clinical evaluation and 
routine laboratory tests at 6- to 12-month intervals will 
suffice. More frequent monitoring and evaluation into 
other causes of liver disease should be initiated in patients 
who develop abnormal ALT levels during the course of 
Patients with abnormal ALT levels who are considered 
to have mild liver disease should undergo clinical assess- 
ment and routine laboratory tests at 6-month intervals. 
The focus of noninvasive monitoring is to detect signs of 
liver disease progression. Monitoring is particularly im- 
portant for patients who choose to defer treatment based 
on the finding of mild liver disease at presentation. Be- 
cause of the poor sensitivity and specificity of clinical ex- 
amination and routine laboratory tests, an abdominal 
ultrasound and possibly a liver biopsy should be consid- 
ered in patients who have clinical and/or laboratory evi- 
dence of liver disease progression. 
Patients with abnormal ALT levels who have a high 
probability of significant hepatic fibrosis or cirrhosis re- 
quire more intense monitoring to detect early signs of 
portal hypertension, hepatic decompensation, and hepa- 
tocellular carcinoma. Thorough clinical evaluation and 
routine laboratory tests should be performed at 6-month 
intervals. Although the efficacy of alpha-fetoprotein and 
ultrasound in the surveillance of hepatocellular carcinoma 
has not yet been proven, these tests are often included in 
the 6-month evaluation of hepatitis C patients who have 
cirrhosis or advanced fibrosis. In addition, surveillance 
upper endoscopy for patients with early cirrhosis is rec- 
ommended to detect esophageal varices and other stig- 
mata of portal hypertension at 2-year intervals.37 
follow-up. 
Future Research Needs 
Significant progress has been made in the development 
of noninvasive tests for the monitoring of patients with 
chronic hepatitis C. Nevertheless, none of the currently 
available tests can completely replace liver histology. Be- 
cause of the variable course of chronic hepatitis C, and the 
complexity of host, virus, and environmental factors that 
may influence liver disease progression, availability of 
noninvasive tests that can be used repeatedly to monitor 
patients with chronic hepatitis C is crucial. These tests 
should be simple, inexpensive, readily available, and ca- 
pable of accurate reflection of the entire spectrum of he- 
patic inflammation and fibrosis in the general population 
of hepatitis C patients. It is likely that no single test will 
fulfill all these criteria. Nevertheless, research to identify 
new serum markers that correlate with hepatic inflamma- 
tion and fibrosis should continue. In addition, studies 
evaluating indices composed of readily available, stan- 
dardized laboratory tests (with or without simple demo- 
graphic data such as age and gender) should be 
encouraged. Indices that show promise need to be vali- 
dated using several laboratories and patient populations, 
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and should be accurate, not only in assessing liver disease 
at initial evaluation but also in tracking disease progres- 
sion during follow-up. These indices should also be sen- 
sitive to the effects of treatment. For these goals to be 
accomplished, clinical centers and basic science laborato- 
ries will need to work together. Studies of noninvasive 
markers should include adequate numbers of patients of 
both sexes and a wide range of ages and ethnicities who 
have the full spectrum of liver disease and who are fol- 
lowed for a sufficient duration of time to capture disease 
progression. Existing clinical databases and serum repos- 
itories from well-characterized patients with hepatitis C 
patients may provide materials for preliminary analysis of 
candidate indices. Prospective multicenter studies involv- 
ing a broader spectrum of patients will be necessary to 
validate these indices. Based on the progress of the last 10 
years, there is every reason to believe that accurate nonin- 
vasive monitoring of patients with chronic hepatitis C can 
become a reality in the next decade. 
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